肝移植领域2016年度重要进展盘点

曾凯宁; 冯啸; 邓宜南; 姜楠

doi:10.3969/j.issn.1674-7445.2017.02.004

肝移植领域2016年度重要进展盘点

doi: 10.3969/j.issn.1674-7445.2017.02.004

510630 广州，中山大学附属第三医院肝脏外科

基金项目:

国家自然科学基金 81572368

广东省自然科学基金 2016A030313278

广东省科技计划项目 2014A020212084

详细信息

通讯作者:
姜楠，Email：njiang163@163.com

中图分类号: R617
计量
- 文章访问数: 70
- HTML全文浏览量: 7
- PDF下载量: 7
- 被引次数: 0
出版历程
- 收稿日期: 2017-02-06
- 网络出版日期: 2021-01-19
- 刊出日期: 2017-03-15

摘要

摘要: 肝移植是目前公认的治疗终末期肝病的最有效措施。经过超过50年的发展，肝移植患者术后存活时间不断延长，并发症的发生率亦有所降低。但是，如何进一步提高肝移植患者的远期疗效，减少并发症的发生以及改善供肝短缺的现状、减轻供肝缺血-再灌注损伤仍然是困扰肝移植医师的难题。因此，了解最新的外科技术、多中心临床经验、以及相关基础研究结果将帮助我们更深入地认识疾病本质，为患者制定更妥善的治疗方案。本文综合国际核心期刊报道的内容，对2016年度肝移植相关领域的研究热点及最新进展作一综述，并对今后的研究方向作出展望。
- 肝移植 /
- 心脏死亡器官捐献 /
- 缺血-再灌注损伤 /
- 并发症 /
- 病毒性肝炎 /
- 肝细胞癌 /
- 免疫抑
- /

HTML全文

参考文献(68)

[1]	Ruiz P, Gastaca M, Valdivieso A, et al. Pre-Mortem Cannulation and NECMO preservation for DCD liver transplantation[J].Am J Transplant, 2016, 16 (suppl 3):150.
[2]	Jessica C, William C, Julie H, et al. Functional warm ischemia in DCD liver transplantation, an international multicentre experience [J]. Transplantation, 2016, 100: s102. doi: 10.1097/TP.0000000000001378
[3]	Weiss E, Hachouf M, Abback PS, et al. Donor's αGST as a predictor graft dysfunction in liver transplantation [EB/OL].(2016-5-6). http://www.abstracts2view.com/ilts/view.php?nu=ILTS16L1_O-117.
[4]	Goldaracena N, Juan E, Moritz K, et al. Adding anti-inflammatory agents during normothermic ex-vivo liver perfusion improves the preservation of pig liver grafts before transplantation[J].Am J Transplant, 2016, 16 (suppl 3): 163. https://www.researchgate.net/publication/292785713_Adding_Anti-Inflammatory_Agents_During_Normothermic_Ex-Vivo_Liver_Perfusion_Improves_the_Preservation_of_Pig_Liver_Grafts_Before_Transplantation
[5]	Palma I, Kabagambe S, Smolin Y, et al. Ex-vivo normothermic perfusion (EVNP) attenuation of kidney ischemia-reperfusion injury (IRI): a proposed mechanism[J].Am J Transplant, 2016, 16 (suppl 3):162.
[6]	Krezdorn N, Kueckelhaus M, Dermietzel A, et al. Ex vivo perfusion of porcine forelimbs to prolong allowable ischemia time [J]. Am J Transplant, 2016, 16 (suppl 3): 162.
[7]	Selzner M, Goldaracena N, Echeverrietal J, et al. Normothermic ex vivo liver perfusion (NEVLP) using steen solution as preservation technique for liver transplantation-first clinical results[EB/OL].(2016-5-5). http://www.abstracts2view.com/ilts/view.php?nu=ILTS16L1_O-63.
[8]	Watson C, Kosmoliaptsis V, Randle L, et al. Extreme hyperoxia during pre-implant normothermic liver perfusion (PINLiP) is associated with post-reperfusion syndrome and vasoplegia[J]. Am J Transplant, 2016, 16 (suppl 3):149.
[9]	Maida K, Akamatsu Y, Hara Y, et al. Short oxygenated warm perfusion with prostaglandin E1 administration before cold preservation as a novel resuscitation method for liver grafts from donors after cardiac death in a rat in vivo model[J]. Transplantation, 2016, 100(5):1052-1058.DOI: 10.1097/TP.0000000000001127.
[10]	Jia JJ, Li JH, Zhou L, et al. Graft protection for liver transplantation: optimized protocol and preclinical study [EB/OL].(2016-5-5). http://www.abstracts2view.com/ilts/view.php?nu=ILTS16L1_P-218.
[11]	Seal J, Bohorquez H, Battula N, et al. Results from 100 consecutive donation-after-circulatory death (DCD) liver transplants using a thrombolytic protocol[J]. Am J Transplant, 2016, 16 (suppl 3): 149.
[12]	Murken D, AufhauserJr D, Wang Z, et al. Histone deacetylase-2 gene deletion in mice mitigates liver ischemia/reperfusion injury[J]. Am J Transplant, 2016, 16 (suppl 3):162.
[13]	Lobb I, Liu W, Jiang J, et al. Hydrogen sulfide treatment mitigates donor tissue necrosis during prolonged cold storage and improves survival following allogeneic renal transplantation. [J]. Am J Transplant, 2016, 16 (suppl 3):163.
[14]	Lee K, Ham Y, Jeon J, et al. NecroX-7 attenuates ischemia-reperfusion renal injury[J]. Am J Transplant, 2016, 16 (suppl 3):162.
[15]	Ye QF, Fan XL, Wang YF, et al.Clinical analysis of 245 cases liver transplantations from china donation after citizen's death[EB/OL].(2016-5-4). http://www.abstracts2view.com/ilts/view.php?nu=ILTS16L1_P-26.
[16]	Vanatta J, Zhao X, Puri V, et al. Outcomes for liver transplantation using organs from donation after cardiac death donors: a single center experience[J]. Am J Transplant, 2016, 16 (suppl 3):150.
[17]	Croome KP, Lee DD, Keaveny AP, et al. Improving national results in liver transplantation using grafts from donation after cardiac death donors[J].Transplantation, 2016, 100(12):2640-2647. doi: 10.1097/TP.0000000000001483
[18]	Verhoeven CJ, Simon TC, de Jonge J, et al. Liver grafts procured from donors after circulatory death have no increased risk of microthrombi formation[J].Liver transpl, 2016, 22(12):1676-1687.DOI: 10.1002/lt.24608.
[19]	Blok JJ, Detry O, Putter H, et al. Longterm results of liver transplantation from donation after circulatory death[J].Liver transpl, 2016, 22(8):1107-1114. DOI: 10.1002/lt.24449.
[20]	Scalea JR, Redfield RR, Foley DP, et al. Some DCD livers function as well as DBD livers: the implications of discarding usable livers[J]. Am J Transplant, 2016, 16 (suppl 3):151.
[21]	Firl DJ, Hashimoto K, O'Rourke C, et al. Role of donor hemodynamic trajectory in determining graft survival in liver transplantation from donation after circulatory death donors [J].Am J Transplant, 2016, 16 (suppl 3):149. https://www.researchgate.net/profile/John_Fung2/publication/307891879_Role_of_Donor_Hemodynamic_Trajectory_in_Determining_Graft_Survival_in_Liver_Transplantation_from_Donation_after_Circulatory_Death_Donors/links/57fe38fc08ae56fae5f2209a.pdf?origin=publication_list
[22]	Samstein B, Smith AR, Freise CE, et al. Complications and their resolution in recipients of deceased and living donor liver transplants: findings from the A2ALL cohort study[J]. Am J Transplant, 2016, 16(2):594-602. DOI: 10.1111/ajt.13479.
[23]	Ghinolfi D, De Simone P, Lai Q, et al. Risk analysis of ischemic-type biliary lesions after liver transplant using octogenarian donors[J]. Liver Transpl, 2016, 22(5):588-598.DOI: 10.1002/lt.24401.
[24]	Zhang YC, Liu W, Fu BS, et al. Therapeutic potentials of umbilical cord-derived mesenchymal stromal cells for ischemic-type biliary lesions following liver transplantation[J]. Cytotherapy, 2017, 19(2):194-199.DOI: 10.1016/j.jcyt.2016.11.005.
[25]	Crespo G, Castro-Narro G, García-Juárez I, et al. Usefulness of liver stiffness measurement during acute cellular rejection in liver transplantation[J].Liver Transpl, 2016, 22(3):298-304. DOI: 10.1002/lt.24376.
[26]	Baumann AK, Schlue J, Noyan F, et al. Preferential accumulation of T helper cells but not cytotoxic T cells characterizes benign subclinical rejection of human liver allografts[J]. Liver Transpl, 2016, 22(7):943-955.DOI: 10.1002/lt.24427.
[27]	Ren Z, Jiang J, Lu H, et al. Intestinal microbial variation may predict early acute rejection after liver transplantation in rats[J].Transplantation, 2014, 98(8):844-852. DOI: 10.1097/TP.0000000000000334.
[28]	Fortún J, Muriel A, Martín-Dávila P, et al. Caspofungin versus fluconazole as prophylaxis of invasive fungal infection in high-risk liver transplantation recipients: a propensity score analysis[J]. Liver Transpl, 2016, 22(4):427-435.DOI: 10.1002/lt.24391.
[29]	Balogh J, Gordon Burroughs S, Boktour M, et al.Efficacy and cost-effectiveness of voriconazole prophylaxis for prevention of invasive aspergillosis in high-risk liver transplant recipients[J]. Liver Transpl, 2016, 22(2):163-170.DOI: 10.1002/lt.24365.
[30]	Viehman JA, Clancy CJ, Clarke L, et al. Surgical site infections after liver transplantation: emergence of multidrug-resistant bacteria and implications for prophylaxis and treatment strategies[J].Transplantation, 2016, 100(10):2107-2114. DOI: 10.1097/TP.0000000000001356.
[31]	Shimizu S, Tanaka Y, Tazawa H, et al. Fc-gamma receptor polymorphisms predispose patients to infectious complications after liver transplantation[J].Am J Transplant, 2016, 16(2):625-633. DOI: 10.1111/ajt.13492.
[32]	Rajakannu M, Awad S, Ciacio O, et al. Intention-to-treat analysis of percutaneous endovascular treatment of hepatic artery stenosis after orthotopic liver transplantation[J].Liver Transpl, 2016, 22(7):923-933. DOI: 10.1002/lt.24468.
[33]	Chu HH, Yi NJ, Kim HC, et al. Longterm outcomes of stent placement for hepatic venous outflow obstruction in adult liver transplantation recipients[J].Liver Transpl, 2016, 22(11): 1554-1561. DOI: 10.1002/lt.24598.
[34]	Wadei HM, Lee DD, Croome KP, et al. Early allograft dysfunction after liver transplantation is associated with short-and long-term kidney function impairment[J].Am J Transplant, 2016, 16(3): 850-859. DOI: 10.1111/ajt.13527.
[35]	VanWagner LB, Serper M, Kang R, et al. Factors associated with major adverse cardiovascular events after liver transplantation among a national sample[J].Am J Transplant, 2016, 16(9):2684-2694. DOI: 10.1111/ajt.13779.
[36]	Perito ER, Lustig RH, Rosenthal P. Metabolic syndrome components after pediatric liver transplantation: prevalence and the impact of obesity and immunosuppression[J].Am J Transplant, 2016, 16(6):1909-1916. DOI: 10.1111/ajt.13714.
[37]	Lenci I, Baiocchi L, Tariciotti L, et al. Complete hepatitis B virus prophylaxis withdrawal in hepatitis B surface antigen-positive liver transplant recipients after longterm minimal immunosuppression[J]. Liver Transpl, 2016, 22(9):1205-1213.DOI: 10.1002/lt.24493.
[38]	Fontana RJ, Brown RS Jr, Moreno-Zamora A, et al. Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection[J]. Liver Transpl, 2016, 22(4):446-458.DOI: 10.1002/lt.24416.
[39]	Crittenden NE, Buchanan LA, Pinkston CM, et al. Simeprevir and sofosbuvir with or without ribavirin to treat recurrent genotype 1 hepatitis C virus infection after orthotopic liver transplantation[J].Liver Transpl, 2016, 22(5):635-643.DOI: 10.1002/lt.24422.
[40]	Dumortier J, Leroy V, Duvoux C, et al. Sofosbuvir-based treatment of hepatitis C with severe fibrosis (METAVIR F3/F4) after liver transplantation[J]. Liver Transpl, 2016, 22(10):1367-1378. DOI: 10.1002/lt.24505.
[41]	Kwok RM, Ahn J, Schiano TD, et al. Sofosbuvir plus ledispasvir for recurrent hepatitis C in liver transplant recipients[J]. Liver Transpl, 2016, 22(11):1536-1543.DOI: 10.1002/lt.24614.
[42]	Cassuto E, Pageaux GP, Cantarovich D, et al. Adherence to and acceptance of once-daily tacrolimus after kidney and liver transplant: results from OSIRIS, a French observational study[J].Transplantation, 2016, 100(10):2099-2106. doi: 10.1097/TP.0000000000001307
[43]	Kim JM, Kwon CH, Joh JW, et al. Conversion of once-daily extended-release tacrolimus is safe in stable liver transplant recipients: a randomized prospective study[J]. Liver Transpl, 2016, 22(2):209-216.DOI: 10.1002/lt.24336.
[44]	Gastaca M, Valdivieso A, Bustamante J, et al. Favorable longterm outcomes of liver transplant recipients treated de novo with once-daily tacrolimus: results of a single-center cohort[J].Liver Transpl, 2016, 22(10):1391-1400. DOI: 10.1002/lt.24514.
[45]	Yanik EL, Chinnakotla S, Gustafson SK, et al. Effects of maintenance immunosuppression with sirolimus after liver transplant for hepatocellular carcinoma[J]. Liver Transpl, 2016, 22(5):627-634. DOI: 10.1002/lt.24395.
[46]	Alver SK, Lorenz DJ, Marvin MR, et al. Projected outcomes of 6-month delay in exception points versus an equivalent Model for End-Stage Liver Disease score for hepatocellular carcinoma liver transplant candidates[J]. Liver Transpl, 2016, 22(10):1343-1355. DOI: 10.1002/lt.24503.
[47]	Young K, Aguilar M, Gish R, et al. Lower rates of receiving model for end-stage liver disease exception and longer time to transplant among nonalcoholic steatohepatitis hepatocellular carcinoma[J].Liver Transpl, 2016, 22(10):1356-1366. DOI: 10.1002/lt.24507.
[48]	Mehta N, Sarkar M, Dodge JL, et al. Intention to treat outcome of T1 hepatocellular carcinoma with the "wait and not ablate" approach until meeting T2 criteria for liver transplant listing[J]. Liver Transpl, 2016, 22(2):178-187.DOI: 10.1002/lt.24360.
[49]	Sapisochin G, Goldaracena N, Laurence JM, et al. The extended Toronto criteria for liver transplantation in patients with hepatocellular carcinoma: a prospective validation study[J]. Hepatology, 2016, 64(6):2077-2088. DOI: 10.1002/hep.28643.
[50]	Murali AR, Romero-Marrero C, Miller C, et al. Predictors of successful downstaging of hepatocellular carcinoma outside Milan criteria[J]. Transplantation, 2016, 100(11): 2391-2397. doi: 10.1097/TP.0000000000001402
[51]	Lee KW, Suh SW, Choi Y, et al. Macrovascular invasion is not an absolute contraindication for living donor liver transplantation[J]. Liver Transpl, 2017, 23(1):19-27. DOI: 10.1002/lt.24610.
[52]	Morita K, Shirabe K, Taketomi A, et al. Relevance of microRNA-18a and microRNA-199a-5p to hepatocellular carcinoma recurrence after living donor liver transplantation[J]. Liver Transpl, 2016, 22(5):665-676. DOI: 10.1002/lt.24400.
[53]	Han S, Yang JD, Sinn DH, et al. Higher bilirubin levels of healthy living liver donors are associated with lower posttransplant hepatocellular carcinoma recurrence[J].Transplantation, 2016, 100(9):1933-1938.DOI: 10.1097/TP.0000000000001293.
[54]	Sharma P, Parikh ND, Yu J, et al. Bone mineral density predicts posttransplant survival among hepatocellular carcinoma liver transplant recipients[J].Liver Transpl, 2016, 22(8):1092-1098. DOI: 10.1002/lt.24458.
[55]	Geissler EK, Schnitzbauer AA, Zülke C, et al. Sirolimus use in liver transplant recipients with hepatocellular carcinoma: a randomized, multicenter, open-label phase 3 trial[J]. Transplantation, 2016, 100(1):116-125. DOI: 10.1097/TP.0000000000000965.
[56]	Jamil KM, Hydes TJ, Cheent KS, et al. STAT4-associated natural killer cell tolerance following liver transplantation[J]. Gut, 2017, 66(2):352-361. DOI: 10.1136/gutjnl-2015-309395.
[57]	Stegmann KA, Robertson F, Hansi N, et al. CXCR6 marks a novel subset of T-bet (lo) Eomes (hi) natural killer cells residing in human liver[J]. Sci Rep, 2016, 6:26157. DOI: 10.1038/srep26157.
[58]	Ningappa M, Ashokkumar C, Higgs BW, et al. Enhanced B cell alloantigen presentation and its epigenetic dysregulation in liver transplant rejection[J]. Am J Transplant, 2016, 16(2):497-508. DOI: 10.1111/ajt.13509.
[59]	Khosravi M, Saadat I, Karimi MH, et al. Association of GSTO2 (N142D) genetic polymorphism and acute rejection of liver[J]. Int J Organ Transplant Med, 2016, 7(3):183-187. https://www.ncbi.nlm.nih.gov/pubmed/27721965
[60]	Shi XL, Mancham S, Hansen BE, et al. Counter-regulation of rejection activity against human liver grafts by donor PD-L1 and recipient PD-1 interaction[J]. J Hepatol, 2016, 64(6):1274-1282. DOI: 10.1016/j.jhep.2016.02.034.
[61]	Vitalone MJ, Wei L, Fujiki M, et al. Liver microRNA profile of induced allograft tolerance[J]. Transplantation, 2016, 100(4):781-790. DOI: 10.1097/TP.0000000000001105.
[62]	Revilla-Nuin B, de Bejar A, Martínez-Alarcón L, et al. Differential profile of activated regulatory T cell subsets and microRNAs in tolerant liver transplant recipients[J]. Liver Transpl, 2016, DOI: 10.1002/lt.24691[Epub ahead of print].
[63]	Todo S, Yamashita K, Goto R, et al. A pilot study of operational tolerance with a regulatory T-cell-based cell therapy in living donor liver transplantation[J]. Hepatology, 2016, 64(2):632-643. DOI: 10.1002/hep.28459.
[64]	Taubert R, Danger R, Londoño MC, et al. Hepatic infiltrates in operational tolerant patients after liver transplantation show enrichment of regulatory T cells before proinflammatory genes are downregulated[J]. Am J Transplant, 2016, 16(4):1285-1293. DOI: 10.1111/ajt.13617.
[65]	Nafady-Hego H, Li Y, Ohe H, et al. Utility of CD127 combined with FOXP3 for identification of operational tolerance after liver transplantation[J]. Transpl Immunol, 2016, 36:1-8. DOI: 10.1016/j.trim.2016.04.005.
[66]	Tang J, Yang R, Lv L, et al. Transforming growth factor-β-expressing mesenchymal stem cells induce local tolerance in a rat liver transplantation model of acute rejection[J]. Stem Cells, 2016, DOI: 10.1002/stem.2437[Epub ahead of print].
[67]	He W, Chen L, Zheng L, et al. Prolonged survival effects induced by immature dendritic cells and regulatory T cells in a rat liver transplantation model[J]. Mol Immunol, 2016, 79:92-97. DOI: 10.1016/j.molimm.2016.10.004.
[68]	Ma B, Yang JY, Song WJ, et al. Combining exosomes derived from immature DCs with donor antigen-specific Treg cells induces tolerance in a rat liver allograft model[J]. Sci Rep, 2016, 6:32971. DOI: 10.1038/srep32971.